Quest Diagnostics

Report Status: Final

Patient Information	Specimen Information	Client Information
DOB: **AGE:** Gender: Fasting: Phone: Patient ID: Health ID:	Specimen: Requisition: Lab Ref #: Collected: Received: Reported:	

COMMENTS: FASTING:YES

Test Name	In Range	Out Of Range	Reference Range	Lab
COMPREHENSIVE METABOLIC PANEL				EN
GLUCOSE	81		65-99 mg/dL Fasting reference interval	
UREA NITROGEN (BUN)	13		7-25 mg/dL	
CREATININE	0.62		0.50-1.10 mg/dL	
eGFR NON-AFR. AMERICAN	113		> OR = 60 mL/min/1.73m2	
eGFR AFRICAN AMERICAN	131		> OR = 60 mL/min/1.73m2	
BUN/CREATININE RATIO	NOT APPLICABLE		6-22 (calc)	
SODIUM	139		135-146 mmol/L	
POTASSIUM	4.2		3.5-5.3 mmol/L	
CHLORIDE	106		98-110 mmol/L	
CARBON DIOXIDE	25		20-31 mmol/L	
CALCIUM	9.7		8.6-10.2 mg/dL	
PROTEIN, TOTAL	6.8		6.1-8.1 g/dL	
ALBUMIN	4.3		3.6-5.1 g/dL	
GLOBULIN	2.5		1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	1.7		1.0-2.5 (calc)	
BILIRUBIN, TOTAL	0.9		0.2-1.2 mg/dL	
ALKALINE PHOSPHATASE	34		33-115 U/L	
AST	14		10-30 U/L	
ALT	10		6-29 U/L	
TSH	0.65		mIU/L Reference Range > or = 20 Years 0.40-4.50 Pregnancy Ranges First trimester 0.26-2.66 Second trimester 0.55-2.73 Third trimester 0.43-2.91	EN
T4, FREE	1.0		0.8-1.8 ng/dL	EN
T3, FREE	3.2		2.3-4.2 pg/mL	EN
ESTROGEN, TOTAL, SERUM	177.7		pg/mL	EZ

Reference Ranges for Total Estrogen:

Follicular Phase (1-12 days):	90-590 pg/mL
Luteal Phase:	130-460 pg/mL
Postmenopausal:	50-170 pg/mL

The total estrogen assay is not recommended for use in pre-pubertal children.

PREGNENOLONE, LC/MS/MS	106		22-237 ng/dL	EZ

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated

Patient Information	Specimen Information	Client Information
DOB: **AGE:** Gender: Fasting: Patient ID: Health ID:	Specimen: Collected: Received: Reported:	

Test Name	In Range	Out Of Range	Reference Range	Lab
pursuant to the CLIA regulations and is used for clinical purposes.				
CBC (INCLUDES DIFF/PLT)				EN
WHITE BLOOD CELL COUNT	4.7		3.8-10.8 Thousand/uL	
RED BLOOD CELL COUNT	4.10		3.80-5.10 Million/uL	
HEMOGLOBIN	12.5		11.7-15.5 g/dL	
HEMATOCRIT	38.6		35.0-45.0 %	
MCV	94.1		80.0-100.0 fL	
MCH	30.5		27.0-33.0 pg	
MCHC	32.4		32.0-36.0 g/dL	
RDW	12.1		11.0-15.0 %	
PLATELET COUNT	238		140-400 Thousand/uL	
MPV	10.8		7.5-12.5 fL	
ABSOLUTE NEUTROPHILS	2632		1500-7800 cells/uL	
ABSOLUTE LYMPHOCYTES	1575		850-3900 cells/uL	
ABSOLUTE MONOCYTES	357		200-950 cells/uL	
ABSOLUTE EOSINOPHILS	108		15-500 cells/uL	
ABSOLUTE BASOPHILS	28		0-200 cells/uL	
ABSOLUTE NUCLEATED RBC	0		0 cells/uL	
NEUTROPHILS	56		%	
LYMPHOCYTES	33.5		%	
MONOCYTES	7.6		%	
EOSINOPHILS	2.3		%	
BASOPHILS	0.6		%	
DHEA SULFATE	137		23-266 mcg/dL	EN
PROGESTERONE	5.4		ng/mL Reference Ranges Female Follicular Phase < 1.0 Luteal Phase 2.6-21.5 Post menopausal < 0.5 Pregnancy 1st Trimester 4.1-34.0 2nd Trimester 24.0-76.0 3rd Trimester 52.0-302.0	EN
ESTRADIOL	87		pg/mL Reference Range Follicular Phase: 19-144 Mid-Cycle: 64-357 Luteal Phase: 56-214 Postmenopausal: < or = 31	EN

Reference range established on post-pubertal patient population. No pre-pubertal reference range established using this assay. For any patients for whom low Estradiol levels are anticipated (e.g. males, pre-pubertal children and hypogonadal/post-menopausal females), the Quest Diagnostics Nichols Institute Estradiol, Ultrasensitive, LCMSMS assay is recommended (order code 30289).

Please note: patients being treated with the drug fulvestrant (Faslodex(R)) have demonstrated significant interference in immunoassay methods for estradiol measurement. The cross reactivity could lead to falsely elevated estradiol test results leading to an

Patient Information	Specimen Information	Client Information
DOB: **AGE:** Gender: Fasting: Patient ID: Health ID: .	Specimen: Collected: Received: Reported:	

Test Name	In Range	Out Of Range	Reference Range	Lab
inappropriate clinical assessment of estrogen status. Quest Diagnostics order code 30289-Estradiol, Ultrasensitive LC/MS/MS demonstrates negligible cross reactivity with fulvestrant.				
SEX HORMONE BINDING GLOBULIN	61		17-124 nmol/L	EN
TESTOSTERONE, TOTAL, LC/MS/MS	26		2-45 ng/dL	SLI
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has not been cleared or approved by the US Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.				

PERFORMING SITE:

EN QUEST DIAGNOSTICS-WEST HILLS, 8401 FALLBROOK AVENUE, WEST HILLS, CA 91304-3226 Laboratory Director: TAB TOOCHINDA,MD, CLIA: 05D0642827
EZ QUEST DIAGNOSTICS/NICHOLS SJC, 33608 ORTEGA HWY, SAN JUAN CAPISTRANO, CA 92675-2042 Laboratory Director: JON NAKAMOTO, MD PHD, CLIA: 05D0643352
SLI QUEST DIAGNOSTICS NICHOLS VALENCIA, 27027 TOURNEY ROAD, VALENCIA, CA 91355-5386 Laboratory Director: BASEL KASHLAN,MD,FCAP, CLIA: 05D0550302